ARTICLE | Strategy
Rules of competition
How companies can compete with gene therapies that provide a functional cure
July 27, 2015 7:00 AM UTC
Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where - even in Orphan diseases - a better product can steal market share. The reason is that if the first gene therapies to market deliver on the promise of a functional cure, there may not be any patients left to treat.
Investors have poured at least $3 billion into 20 companies developing gene therapies for Orphan indications that have one or more competitors working on the same gene - including $1 billion to bluebird bio Inc. alone. Most of these companies have touted potential benefits of their products over more advanced competitors targeting the same genes...